IgA Nephropathy in a Patient With Metastatic Carcinoma of Unknown Primary

2022 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Shuhui Huang ◽  
Zhibing Qi ◽  
Rui Huang ◽  
Minggang Su
2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 20024-20024
Author(s):  
D. Talantov ◽  
J. Baden ◽  
T. Jatkoe ◽  
J. Yu ◽  
D. Atkins ◽  
...  

20024 Background: Carcinoma of unknown primary (CUP) wherein metastatic disease presents without an identifiable primary tumor site represents approximately 3–5% of all cancers. Identifying the origin of the primary tumor in patients with CUP can enable rational choice of therapeutic regimens. We developed an optimized set of ten gene markers for a quantitative reverse transcriptase polymerase chain reaction (qRTPCR) assay, and demonstrated high accuracy in predicting the tissue of origin when used on with formalin-fixed, paraffin-embedded (FFPE) metastatic carcinoma samples. Methods: Twenty-three putative tissue-specific markers for lung, colon, pancreas, breast, prostate and ovarian carcinomas were nominated by querying a gene expression profile database and by performing a literature search. Ten of these marker candidates were then selected based on validation by qRTPCR on 205 FFPE metastatic carcinomas of known tissue origin. Next, we optimized the RNA isolation and qRTPCR methods for these ten markers, and tested the qRTPCR assay on two sets of FFPE metastatic tumors. Results: We applied the 10-gene qRTPCR assay to a set of 260 metastatic tumors of known origin, generating an overall accuracy of 78%. Furthermore we tested an independent set of 48 metastatic samples, including thirty-seven samples where either the tissue of origin was known or which initially presented as CUP but were subsequently resolved. In these 48 samples, our assay demonstrated an accuracy of 76%. Conclusions: Our results suggested that optimized ten-gene markers qRTPCR assay reliably predicts tissue of origin of metastatic carcinomas in FFPE tissues. Such assay can significantly improve the rate of tissue of origin identification for carcinoma of unknown primary. [Table: see text]


2018 ◽  
pp. bcr-2017-223970 ◽  
Author(s):  
Sonia Rupal Sharma ◽  
Douglas Maslin ◽  
Sui-Yen Ah-See ◽  
Pamela Todd

2019 ◽  
Vol 7 ◽  
pp. 2050313X1983873
Author(s):  
Pedro Luiz Serrano Usón Junior ◽  
Jairo Wagner ◽  
Marcus Vinicius de Nigro Corpa ◽  
Iracema Moraes Coelho ◽  
Robert A Nagourney ◽  
...  

Background: The treatment of carcinoma of unknown primary based on histopathology and immunohistochemistry is generally chemotherapy. The use of molecular markers, genetic profiling platforms, and personalized medicine is under active investigation. Case Report: We report the case of a 56-year-old patient who presented to medical attention with palpable axillary adenopathy. Biopsy confirmed poorly differentiated adenocarcinoma. Formal staging revealed extensive metastatic disease to bone and liver. Initial chemotherapy proved ineffective. We describe the diagnostic evaluation, treatment, and achievement of durable remission using a novel sorafenib-based drug combination that was chosen through the application of a functional analytic laboratory platform. Conclusion: The clinical management of patients with carcinoma of unknown primary continues to present a considerable challenge for practicing oncologists. Laboratory platforms capable of examining cellular response to injury, growth factor withdrawal, and cytotoxic insult at the level of cellular function may provide insights for drug selection in this patient population.


Sign in / Sign up

Export Citation Format

Share Document